ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2019
Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Systematic review: gastrointestinal infection and incident inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2020Pooled it
- Silk-based biomimetic nanocomposite for precision eradication of Helicobacter pylori and gut microbiome preservation.Journal of nanobiotechnology · 2026Article
- The effects of Helicobacter pylori eradication and development of immune-mediated disorder in children: a nationwide population-based study in Korea.The Korean journal of internal medicine · 2026Article
- Review
- Helicobacter pylori infection might be a protective factor against Parkinson's disease.Scientific reports · 2025Article
- Emerging novel hydrogels application in oral and gastrointestinal diseases: design wet adhesive strategy towards possible mechanisms.Science and technology of advanced materials · 2025Review
- Immune Cell Crisis and Excess Histopathological Features During the Development and Progression ofInternational journal of general medicine · 2025Article
- Impact ofJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
- Immune cell changes inAnnals of medicine · 2024Article
- Association ofBMJ open · 2024Article
- Impact ofDiseases (Basel, Switzerland) · 2024Review
- Common diagnostic biomarkers and molecular mechanisms ofFrontiers in immunology · 2024Article
- Immunological relationship betweenCentral-European journal of immunology · 2024Review
- Disease trends afterWorld journal of gastroenterology · 2023Article
- Review
- Early onset, development and histological features of gastric signet-ring cell carcinoma.Frontiers in oncology · 2023Article
- Rights and wrongs ofTherapeutic advances in gastroenterology · 2023Article
- Implications of the changing epidemiology of inflammatory bowel disease in a changing world.United European gastroenterology journal · 2022Review
- Cost-effectiveness of screening with polymerase chain reaction forJournal of gastrointestinal oncology · 2022Article
- Observational
Corrections and comments
- Commented on by
- Commented on byReply.2019
- Commented on by
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsHelicobacter pylori induces immune tolerance and is associated with a lower risk for immune-mediated disorders, such as autoimmune and inflammatory bowel diseases (IBD). We aimed to determine the effects of treatment for H pylori infection on the incidence of autoimmune disease and IBD.
methodsWe collected data from the National Health Insurance Research Database in Taiwan on patients younger than 18 years old without a prior diagnosis of autoimmune disease or IBD. Patients with peptic ulcer disease (PUD) with treatment of H pylori infection (PUD+HPRx), PUD without H pylori treatment (PUD-HPRx), a urinary tract infection (UTI) treated with cephalosporin, or without PUD (controls) were matched for age, sex, insurance, and Charlson's comorbidity index score.
resultsOf the 1 million patients we collected data from in 2005, we included 79,181 patients in the study. We compared the effects of treatment for H pylori infection on the risk of autoimmunity or IBD and found that PUD+HPRx has the highest adjusted hazard risk (aHR) for autoimmunity or IBD (aHR, 2.36), compared to PUD-HPRx (aHR, 1.91) or UTI (aHRs, 1.71) (P < .001). The increased risk of autoimmune disease was not completely accounted for by antibiotic therapy alone, because PUD+HPRx had a higher aHR than UTI (P < .001). A small but significant increase in mortality was observed in the PUD+HPRx cohort (aHR, 1.11; P = .001).
conclusionIn an analysis of data from the National Health Insurance Research Database in Taiwan, we found that treatment for H pylori infection is associated with a significant increase in the risk for autoimmune disease, including IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.